{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:20:39Z","timestamp":1790785239967,"version":"4.1.0"},"reference-count":144,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.phrs.2020.104859","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T12:39:13Z","timestamp":1588163953000},"page":"104859","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":427,"special_numbering":"C","title":["Candidate drugs against SARS-CoV-2 and COVID-19"],"prefix":"10.1016","volume":"157","author":[{"given":"Dwight L.","family":"McKee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Stange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Laufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cord","family":"Naujokat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10224","key":"10.1016\/j.phrs.2020.104859_bib0005","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.phrs.2020.104859_bib0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China","volume":"383","author":"Zhu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.104859_bib0015","unstructured":"https:\/\/coronavirus.jhu.edu\/map.html Johns Hopkins University, USA, (2020)."},{"key":"10.1016\/j.phrs.2020.104859_bib0020","doi-asserted-by":"crossref","first-page":"104285","DOI":"10.1016\/j.meegid.2020.104285","article-title":"Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species","volume":"82","author":"Li","year":"2020","journal-title":"Infect. Genet. Evol."},{"issue":"1","key":"10.1016\/j.phrs.2020.104859_bib0025","doi-asserted-by":"crossref","first-page":"vex012","DOI":"10.1093\/ve\/vex012","article-title":"Global patterns in coronavirus diversity","volume":"3","author":"Anthony","year":"2017","journal-title":"Virus Evol."},{"issue":"6","key":"10.1016\/j.phrs.2020.104859_bib0030","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.phrs.2020.104859_bib0035","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.aivir.2019.08.002","article-title":"Structural insights into coronavirus entry","volume":"105","author":"Tortorici","year":"2019","journal-title":"Adv. Virus Res."},{"issue":"March 4","key":"10.1016\/j.phrs.2020.104859_bib0040","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease receptor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"March 6","key":"10.1016\/j.phrs.2020.104859_bib0045","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.phrs.2020.104859_bib0050","first-page":"217","article-title":"The outbreak of COVID-19: an overview, J. Chin","volume":"83","author":"Wu","year":"2020","journal-title":"Med. Assoc."},{"issue":"8","key":"10.1016\/j.phrs.2020.104859_bib0055","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.104859_bib0060","first-page":"248","article-title":"An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov)","volume":"5","author":"Tang","year":"2020","journal-title":"Infect. Dis. Model."},{"key":"10.1016\/j.phrs.2020.104859_bib0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"B\u00e1ez-Santos","year":"2015","journal-title":"Antiviral Res."},{"issue":"5","key":"10.1016\/j.phrs.2020.104859_bib0070","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV","volume":"21","author":"Morse","year":"2020","journal-title":"Chembiochem."},{"issue":"1","key":"10.1016\/j.phrs.2020.104859_bib0075","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.phrs.2020.104859_bib0080","doi-asserted-by":"crossref","first-page":"e:35876","DOI":"10.1371\/journal.pone.0035876","article-title":"Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts","volume":"7","author":"Bertram","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104859_bib0085","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","article-title":"Protease inhibitors targeting coronavirus and filovirus entry","volume":"116","author":"Zhou","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.phrs.2020.104859_bib0090","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pupt.2015.07.001","article-title":"The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells","volume":"33","author":"Yamaya","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"24","key":"10.1016\/j.phrs.2020.104859_bib0095","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01542-10","article-title":"Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2","volume":"84","author":"Matsuyama","year":"2010","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.phrs.2020.104859_bib0100","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/JVI.02062-10","article-title":"A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry","volume":"85","author":"Shulla","year":"2011","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.phrs.2020.104859_bib0105","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/JVI.02232-10","article-title":"Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response","volume":"85","author":"Glowacka","year":"2011","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.phrs.2020.104859_bib0110","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/JVI.00094-12","article-title":"Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry","volume":"86","author":"Kawase","year":"2012","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.phrs.2020.104859_bib0115","first-page":"1053","article-title":"Effect of the synthetic protease inhibitor [N,N-dimethylcarbamoyl-methyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on carcinogenesis by 3-methylcholanthrene in mouse skin","volume":"71","author":"Ohkoshi","year":"1983","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.phrs.2020.104859_bib0120","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0301-0503(84)80235-0","article-title":"Clinical experience with a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate for prevention of recurrence of carcinoma of the mouth and in treatment of terminal carcinoma","volume":"12","author":"Ohkoshi","year":"1984","journal-title":"J. Maxillofac. Surg."},{"issue":"16","key":"10.1016\/j.phrs.2020.104859_bib0125","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0190-9622(88)70130-9","article-title":"Protease inhibitor therapy for recessive dystrophic epidermolysis bullosa. In vitro effect and clinical trial with camostat mesylate","volume":"18","author":"Ikeda","year":"1988","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.phrs.2020.104859_bib0130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000199102","article-title":"Effect of a specific serine protease inhibitor on the rat pancreas: systemic administration of camostate and exocrine pancreatic secretion","volume":"30","author":"G\u00f6ke","year":"1984","journal-title":"Digestion"},{"issue":"1","key":"10.1016\/j.phrs.2020.104859_bib0135","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2362.1988.tb01173.x","article-title":"Stimulation of pancreatic secretion in man by a protease inhibitor (camostate)","volume":"18","author":"Adler","year":"2020","journal-title":"Eur. J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.phrs.2020.104859_bib0140","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00535-009-0148-1","article-title":"Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease","volume":"45","author":"Sai","year":"2010","journal-title":"J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.phrs.2020.104859_bib0145","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000492813","article-title":"Camostat mesilate, pancrelipase, and rabeprazole combination therapy improves epigastric pain in early chronic pancreatitis and functional dyspepsia with pancreatic enzyme abnormalities","volume":"99","author":"Yamawaki","year":"2019","journal-title":"Digestion"},{"issue":"1","key":"10.1016\/j.phrs.2020.104859_bib0150","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s13063-019-3606-y","article-title":"A phase 1\/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with Chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC)","volume":"20","author":"Ramsey","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.phrs.2020.104859_bib0155","unstructured":"NCT02693093, ClinicalTrials.gov, (2016), Feb 26."},{"issue":"2","key":"10.1016\/j.phrs.2020.104859_bib0160","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1254\/jjp.41.155","article-title":"Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats","volume":"41","author":"Iwako","year":"1986","journal-title":"Jpn. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2020.104859_bib0165","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/039139888801100316","article-title":"Plasma collection using nafamostat mesilate and dipyridamole as an anticoagulant","volume":"11","author":"Hiraishi","year":"1988","journal-title":"Int. J. Artif. Organs"},{"issue":"3","key":"10.1016\/j.phrs.2020.104859_bib0170","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00535-019-01644-z","article-title":"Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial","volume":"55","author":"Hirota","year":"2020","journal-title":"J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.phrs.2020.104859_bib0175","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1128\/AAC.01043-16","article-title":"Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.phrs.2020.104859_bib0180","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"6965","key":"10.1016\/j.phrs.2020.104859_bib0185","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronoavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"issue":"7477","key":"10.1016\/j.phrs.2020.104859_bib0190","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nature12711","article-title":"Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor","volume":"503","author":"Ge","year":"2013","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.phrs.2020.104859_bib0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007236","article-title":"Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2","volume":"14","author":"Song","year":"2018","journal-title":"PLoS Pathol."},{"issue":"4","key":"10.1016\/j.phrs.2020.104859_bib0200","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1139\/y02-021","article-title":"ACEH\/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors","volume":"80","author":"Turner","year":"2002","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2020.104859_bib0205","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2020.104859_bib0210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","article-title":"New insights into the antiviral effects of chloroquine","volume":"6","author":"Savarino","year":"2006","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.phrs.2020.104859_bib0215","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/cr.2012.165","article-title":"Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model","volume":"32","author":"Yan","year":"2013","journal-title":"Cell Res."},{"issue":"August 22","key":"10.1016\/j.phrs.2020.104859_bib0220","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.phrs.2020.104859_bib0225","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al-Bari","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"issue":"1","key":"10.1016\/j.phrs.2020.104859_bib0230","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","article-title":"In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine","volume":"323","author":"Keyaerts","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"March 9","key":"10.1016\/j.phrs.2020.104859_bib0235","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2020.104859_bib0240","doi-asserted-by":"crossref","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci. Trends"},{"issue":"13","key":"10.1016\/j.phrs.2020.104859_bib0245","first-page":"213","article-title":"Medication for COVID-19 \u2013 an overview of approaches currently under study","volume":"117","author":"Stahlmann","year":"2020","journal-title":"Arztebl."},{"issue":"March 20","key":"10.1016\/j.phrs.2020.104859_bib0250","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a tratment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"March 31","key":"10.1016\/j.phrs.2020.104859_bib0255","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRXiv"},{"issue":"February 28","key":"10.1016\/j.phrs.2020.104859_bib0260","article-title":"Clinical trial analysis of 2019-nCoV therapy registered in China","author":"Zhang","year":"2020","journal-title":"J. Med. Virol."},{"issue":"March 10","key":"10.1016\/j.phrs.2020.104859_bib0265","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","author":"Cortegiani","year":"2020","journal-title":"J. Crit. Care"},{"issue":"March 13","key":"10.1016\/j.phrs.2020.104859_bib0270","first-page":"1","article-title":"COVID-19: An update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western medicine for the management of 2019 novel coronavirus disease","author":"Chan","year":"2020","journal-title":"Am. J. Chin. Med. (Gard City N Y)"},{"key":"10.1016\/j.phrs.2020.104859_bib0275","unstructured":"NCT04303507, ClinicalTrials.gov, (2020), Mar 11."},{"key":"10.1016\/j.phrs.2020.104859_bib0280","unstructured":"NCT04303299, ClinicalTrials.gov, (2020), Mar 11."},{"issue":"September","key":"10.1016\/j.phrs.2020.104859_bib0285","doi-asserted-by":"crossref","first-page":"152956","DOI":"10.1016\/j.phymed.2019.152956","article-title":"Cepharanthine: An update of its mode of action, pharmacological properties and medical applications","volume":"62","author":"Bailly","year":"2019","journal-title":"Phytomedicine"},{"issue":"6","key":"10.1016\/j.phrs.2020.104859_bib0290","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00213-018-4869-9","article-title":"Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders","volume":"235","author":"Khoja","year":"2018","journal-title":"Psychopharmacology (Berl.)"},{"issue":"October 30","key":"10.1016\/j.phrs.2020.104859_bib0295","article-title":"Mefloquine for preventing malaria during travel to endemic areas","volume":"10","author":"Tickell-Painter","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"March 6","key":"10.1016\/j.phrs.2020.104859_bib0300","article-title":"Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model","author":"Fan","year":"2020","journal-title":"Chin. Med. J."},{"issue":"18","key":"10.1016\/j.phrs.2020.104859_bib0305","doi-asserted-by":"crossref","first-page":"15532","DOI":"10.1074\/jbc.M212934200","article-title":"Novel peptide inhibitors of angiotensin-converting enzyme 2","volume":"278","author":"Huang","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2020.104859_bib0310","doi-asserted-by":"crossref","first-page":"R1293","DOI":"10.1152\/ajpregu.00339.2011","article-title":"Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays","volume":"301","author":"Pedersen","year":"2011","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2020.104859_bib0315","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1161\/HYPERTENSIONAHA.112.198622","article-title":"Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2","volume":"60","author":"Ye","year":"2012","journal-title":"Hypertension"},{"issue":"14","key":"10.1016\/j.phrs.2020.104859_bib0320","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1111\/j.1742-4658.2005.04756.x","article-title":"Identification of critical active-site residues in angiotensin-converting enzyme 2 (ACE2) by site-directed mautagenesis","volume":"272","author":"Guy","year":"2005","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.phrs.2020.104859_bib0325","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.virol.2006.01.029","article-title":"Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor","volume":"350","author":"Han","year":"2006","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.phrs.2020.104859_bib0330","first-page":"2216","article-title":"Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2, J. Med","volume":"51","author":"Mores","year":"2008","journal-title":"Chem."},{"issue":"6","key":"10.1016\/j.phrs.2020.104859_bib0335","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/ajh.2010.51","article-title":"Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats","volume":"23","author":"Trask","year":"2010","journal-title":"Am. J. Hypertens."},{"issue":"6","key":"10.1016\/j.phrs.2020.104859_bib0340","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1161\/01.HYP.0000146120.29648.36","article-title":"Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor","volume":"44","author":"Huentelmann","year":"2004","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.phrs.2020.104859_bib0345","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.antiviral.2009.12.001","article-title":"TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds","volume":"85","author":"Haga","year":"2010","journal-title":"Antiviral Res."},{"issue":"6486","key":"10.1016\/j.phrs.2020.104859_bib0350","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/370218a0","article-title":"Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing","volume":"370","author":"Mohler","year":"1994","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.phrs.2020.104859_bib0355","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1105\/tpc.010256","article-title":"Role of nicotianamide in the intracellular delivery of metals and plant reproductive development","volume":"15","author":"Takahashi","year":"2003","journal-title":"Plant Cell"},{"issue":"3","key":"10.1016\/j.phrs.2020.104859_bib0360","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2220\/biomedres.36.219","article-title":"Nicotianamide is a novel angiotensin-converting enzyme 2 inhibitor in soybean","volume":"36","author":"Takahashi","year":"2015","journal-title":"Biomed. Res."},{"issue":"February 27","key":"10.1016\/j.phrs.2020.104859_bib0365","article-title":"The \"big five\" phytochemicals targeting cancer stem cells: curcumin, EGCG, sulforaphane, resveratrol and genistein","author":"Naujokat","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phrs.2020.104859_bib0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV2 infections in engineered human tissues using clinical-grade soluble human ACE2","author":"Monteil","year":"2020","journal-title":"Cell"},{"issue":"7594","key":"10.1016\/j.phrs.2020.104859_bib0375","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2020.104859_bib0380","doi-asserted-by":"crossref","first-page":"43395","DOI":"10.1038\/srep43395","article-title":"GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses","volume":"7","author":"Lo","year":"2017","journal-title":"Sci. Rep."},{"issue":"396","key":"10.1016\/j.phrs.2020.104859_bib0385","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.phrs.2020.104859_bib0390","doi-asserted-by":"crossref","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio."},{"issue":"4","key":"10.1016\/j.phrs.2020.104859_bib0395","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/v11040326","article-title":"Mechanisms of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir","volume":"11","author":"Tchesnokov","year":"2019","journal-title":"Viruses"},{"issue":"February 24","key":"10.1016\/j.phrs.2020.104859_bib0400","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from middle east respiratory syndrome coronavirus","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"issue":"February 13","key":"10.1016\/j.phrs.2020.104859_bib0405","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the 345 rhesus macaque model of MERS-CoV infection","author":"de Wit","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"24","key":"10.1016\/j.phrs.2020.104859_bib0410","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"April 10","key":"10.1016\/j.phrs.2020.104859_bib0415","article-title":"Compassionate use of remdesivir for patients with severe COVID-19","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.104859_bib0420","unstructured":"NCT04252664, ClinicalTrials.gov, (2020), Feb 5."},{"key":"10.1016\/j.phrs.2020.104859_bib0425","unstructured":"NCT04257656, ClinicalTrials.gov, (2020), Feb 6."},{"key":"10.1016\/j.phrs.2020.104859_bib0430","unstructured":"NCT04280705, ClinicalTrials.gov, (2020), Feb 21."},{"key":"10.1016\/j.phrs.2020.104859_bib0435","unstructured":"NCT04292730, ClinicalTrials.gov, (2020), Mar 3."},{"key":"10.1016\/j.phrs.2020.104859_bib0440","unstructured":"NCT04292899, ClinicalTrials.gov, (2020), Mar 3."},{"key":"10.1016\/j.phrs.2020.104859_bib0445","unstructured":"NCT04302766, ClinicalTrials.gov, (2020), Mar 10."},{"key":"10.1016\/j.phrs.2020.104859_bib0450","unstructured":"NCT04314817, ClinicalTrials.gov, (2020), Mar 19."},{"key":"10.1016\/j.phrs.2020.104859_bib0455","unstructured":"NCT04315948, ClinicalTrials.gov, (2020), Mar 20."},{"issue":"12","key":"10.1016\/j.phrs.2020.104859_bib0460","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1128\/AAC.42.12.3218","article-title":"ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease","volume":"42","author":"Sham","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.phrs.2020.104859_bib0465","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1086\/339014","article-title":"Safety and antiviral activity at 48 weeks of lopinavir\/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients","volume":"185","author":"Benson","year":"2002","journal-title":"J. Infect. Dis."},{"issue":"7-8","key":"10.1016\/j.phrs.2020.104859_bib0470","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1345\/aph.1A363","article-title":"Kaletra (lopinavir\/ritonavir)","volume":"36","author":"Corbett","year":"2002","journal-title":"Ann. Pharmacother."},{"issue":"3","key":"10.1016\/j.phrs.2020.104859_bib0475","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.phrs.2020.104859_bib0480","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2020.104859_bib0485","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13063-019-3846-x","article-title":"Treatment of Middle East respiratory syndrome with a combination of lopinavir\/ritonavir and interferon-\u03b21b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial","volume":"21","author":"Arabi","year":"2020","journal-title":"Trials"},{"issue":"March 18","key":"10.1016\/j.phrs.2020.104859_bib0490","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.104859_bib0495","unstructured":"NCT04255017, ClinicalTrials.gov, (2020), Feb 5."},{"key":"10.1016\/j.phrs.2020.104859_bib0500","unstructured":"NCT04261907, ClinicalTrials.gov, (2020), Feb 10."},{"key":"10.1016\/j.phrs.2020.104859_bib0505","unstructured":"NCT04286503, ClinicalTrials.gov, (2020), Feb 27."},{"key":"10.1016\/j.phrs.2020.104859_bib0510","unstructured":"NCT04295551, ClinicalTrials.gov, (2020), Mar 4."},{"key":"10.1016\/j.phrs.2020.104859_bib0515","unstructured":"NCT04276688, ClinicalTrials.gov, (2020), Feb 19."},{"key":"10.1016\/j.phrs.2020.104859_bib0520","unstructured":"NCT04307693, ClinicalTrials.gov, (2020), Mar 13."},{"key":"10.1016\/j.phrs.2020.104859_bib0525","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad sprctrum antivital: un update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antiviral Res."},{"issue":"2","key":"10.1016\/j.phrs.2020.104859_bib0530","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2008.10.009","article-title":"Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol","volume":"81","author":"Leneva","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.phrs.2020.104859_bib0535","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1743-422X-3-56","article-title":"Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection","volume":"3","author":"Boriskin","year":"2006","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.phrs.2020.104859_bib0540","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.antiviral.2013.08.008","article-title":"Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking","volume":"100","author":"Blaising","year":"2013","journal-title":"Antiviral Res."},{"issue":"6","key":"10.1016\/j.phrs.2020.104859_bib0545","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/JVI.02077-15","article-title":"The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses","volume":"90","author":"P\u00e9cheur","year":"2016","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.phrs.2020.104859_bib0550","doi-asserted-by":"crossref","first-page":"e02185","DOI":"10.1128\/JVI.02185-18","article-title":"Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses","volume":"93","author":"Hulseberg","year":"2019","journal-title":"J. Virol."},{"issue":"March 16","key":"10.1016\/j.phrs.2020.104859_bib0555","article-title":"Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China","author":"Wang","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"March 11","key":"10.1016\/j.phrs.2020.104859_bib0560","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against corona virus disease 2019: a retrospective cohort study","author":"Deng","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.phrs.2020.104859_bib0565","unstructured":"NCT04255017, ClinicalTrials.gov, (2020), Feb 5."},{"key":"10.1016\/j.phrs.2020.104859_bib0570","unstructured":"NCT04260594, ClinicalTrials.gov, (2020), Feb 7."},{"key":"10.1016\/j.phrs.2020.104859_bib0575","unstructured":"NCT04273763, ClinicalTrials.gov, (2020), Feb 18."},{"key":"10.1016\/j.phrs.2020.104859_bib0580","unstructured":"NCT04286503, ClinicalTrials.gov, (2020), Feb 27."},{"issue":"4","key":"10.1016\/j.phrs.2020.104859_bib0585","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.phrs.2020.104859_bib0590","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"A broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad., Ser. B, Phys. Biol. Sci."},{"issue":"7","key":"10.1016\/j.phrs.2020.104859_bib0595","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5\u2019-triphosphate towards influenza A virus polymerase","volume":"8","author":"Jin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2020.104859_bib0600","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.phrs.2020.104859_bib0605","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antiviral Res."},{"issue":"3","key":"10.1016\/j.phrs.2020.104859_bib0610","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.phrs.2020.104859_bib0615","unstructured":"NCT04310228, ClinicalTrials.gov, (2020), Mar 17."},{"key":"10.1016\/j.phrs.2020.104859_bib0620","unstructured":"NCT04303299, ClinicalTrials.gov, (2020), Mar 11."},{"issue":"5626","key":"10.1016\/j.phrs.2020.104859_bib0625","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main protease (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"issue":"March 20","key":"10.1016\/j.phrs.2020.104859_bib0630","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"April 9","key":"10.1016\/j.phrs.2020.104859_bib0635","article-title":"Structure of Mpro from COVID-19 virus and discovery of its inhibitors","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2020.104859_bib0640","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.taap.2018.06.022","article-title":"Flavonoids interfere with NLRP3 inflammasome activation","volume":"355","author":"Lim","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"50","key":"10.1016\/j.phrs.2020.104859_bib0645","article-title":"Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.phrs.2020.104859_bib0650","first-page":"265","article-title":"Luteolin alleviates NLRP3 inflammasome activation and directs macrophage polarization in lipopolysaccharide-stimulated RAW264.7 cells","volume":"10","author":"Zhang","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.phrs.2020.104859_bib0655","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.taap.2018.12.019","article-title":"Myricetin inhibits NLRP3 inflammasome activation via reduction of ROS-dependent ubiquitination of ASC and promotion of ROS-independent NLRP3 ubiquitination","volume":"365","author":"Chen","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2020.104859_bib0660","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/FJC.0000000000000747","article-title":"Dietary apigenin reduces induction of LOX-1 and NLRP3 expression, leukocyte adhesion, and acetylated low-density lipoprotein uptake in human endothelial cells exposed to trimethylamine-N-oxide","volume":"74","author":"Yamagata","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2020.104859_bib0665","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s10753-017-0542-4","article-title":"Quercetin and ascorbic acid suppress fructose-induced NLRP3 inflammasome activation by blocking intracellular shuttling of TXNIP in human macrophage cell lines","volume":"40","author":"Choe","year":"2017","journal-title":"Inflammation"},{"key":"10.1016\/j.phrs.2020.104859_bib0670","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.taap.2018.06.022","article-title":"Flavonoids interfere with NLRP3 inflammasome activation","volume":"355","author":"Lim","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2020.104859_bib0675","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13567-016-0359-4","article-title":"Baicalin suppresses NLRP3 inflammasome and nuclear factor-kappa B (NF-\u03baB) signaling during haemophilus parasuis infection","volume":"47","author":"Fu","year":"2016","journal-title":"Vet. Res."},{"issue":"2","key":"10.1016\/j.phrs.2020.104859_bib0680","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bcp.2015.02.002","article-title":"Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-\u03baB and NLRP3 inflammasome activation","volume":"94","author":"Sun","year":"2015","journal-title":"Biochem. Pharmacol."},{"issue":"7","key":"10.1016\/j.phrs.2020.104859_bib0685","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/v11070625","article-title":"Antiviral efficacy of lavonoids against enterovirus 71 infection in vitro and in newborn mice","volume":"11","author":"Dai","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.phrs.2020.104859_bib0690","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1038\/srep05452","article-title":"Baicalin, a metabolite of baicalein with antiviral activity against dengue virus","volume":"4","author":"Moghaddam","year":"2014","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.phrs.2020.104859_bib0695","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.antiviral.2006.04.014","article-title":"Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction","volume":"74","author":"Ho","year":"2007","journal-title":"Antiviral Res."},{"issue":"1","key":"10.1016\/j.phrs.2020.104859_bib0700","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12879-017-2253-8","article-title":"Effective inhibition of MERS-CoV infection by resveratrol","volume":"17","author":"Lin","year":"2017","journal-title":"BMC Infect. Dis."},{"issue":"March 2","key":"10.1016\/j.phrs.2020.104859_bib0705","article-title":"WHO launches global megatrial of the four most promising coronavirus treatments","author":"Kupferschmidt","year":"2020","journal-title":"Science"},{"issue":"March 19","key":"10.1016\/j.phrs.2020.104859_bib0710","article-title":"Use of antiviral drugs to reduce COVID-19 transmission","author":"Mitja","year":"2020","journal-title":"Lancet Glob. Health"},{"issue":"April 1","key":"10.1016\/j.phrs.2020.104859_bib0715","article-title":"Virological assessment of hospitalized patients with COVID-19","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"issue":"April 4","key":"10.1016\/j.phrs.2020.104859_bib0720","article-title":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice","author":"Sheahan","year":"2020","journal-title":"Sci. Transl. Med."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820311671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820311671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:09:23Z","timestamp":1760911763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820311671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":144,"alternative-id":["S1043661820311671"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104859","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737863617.793574761","asserted-by":"object"}]},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Candidate drugs against SARS-CoV-2 and COVID-19","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104859","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104859"}}